Entyvio produces higher UC remission rates than anti-TNF
Click Here to Manage Email Alerts
Patients with ulcerative colitis who received Entyvio in routine practice experienced higher rates of remission than those treated with anti-TNF agents, according to study results.
Parambir Dulai, MD, of the division of gastroenterology at the University of California, San Diego, and colleagues wrote that recent phase 3 studies demonstrated the superiority of Entyvio (vedolizumab, Takeda) over anti-TNF, but more information is needed on how effective it is in everyday practice.
“Although informative in helping to understand the relative positioning of these biologics, nearly 75% of UC patients seen in routine practice do not qualify for these phase 3 trial programs,” they wrote. “Direct routine practice comparative studies are needed to fully inform treatment decisions.”
Researchers explored data from patients with UC treated with vedolizumab (n = 454) or anti-TNF (n = 268) from May 2014 to December 2017. They compared development of serious adverse events, as well as rates of clinical remission, steroid-free clinical remission, and steroid-free deep remission between the two groups.
Investigators found that patients treated with vedolizumab were more likely to achieve clinical remission (HR = 1.651; 95% CI, 1.229–2.217), steroid-free clinical remission (HR = 1.828; 95% CI, 1.135–2.944) and steroid-free deep remission (HR = 2.819; 95% CI, 1.496–5.31). The results were consistent among patients who were naive or exposed to anti-TNF treatment.
Researchers found no overall difference between the two groups regarding serious adverse events or serious infections. However, among patients naive to anti-TNF treatment, vedolizumab was less likely to be associated with serious adverse events than anti-TNF therapies (HR = 0.192; 95% CI, 0.049–0.754).
“Data generated from this routine clinical practice comparative study may help to bridge gaps in understanding the appropriate positioning of biologic therapies in UC,” Dulai and colleagues wrote. “Although cost-effectiveness will need to be assessed, particularly considering the emerging availability of biosimilars in the United States market, our work could be of substantial value for informing policy decisions to ensure equal access to safe and effective therapies for all patients.”
Collapse
Read more about
Click Here to Manage Email Alerts